Loading...
XHKG
8329
Market cap30mUSD
Dec 05, Last price  
0.14HKD
1D
2.14%
1Q
-10.63%
Jan 2017
-70.52%
IPO
-57.31%
Name

Shenzhen Neptunus Interlong Bio-technique Co Ltd

Chart & Performance

D1W1MN
XHKG:8329 chart
P/E
8.71
P/S
0.21
EPS
0.01
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-0.74%
Revenues
1.04b
-2.18%
20,181,00016,160,00016,310,0003,696,00038,256,000474,652,000530,458,000611,666,000648,268,000721,346,000759,111,000790,286,000867,123,0001,080,871,0001,031,369,000838,805,000986,691,0001,064,861,0001,041,698,000
Net income
25m
+3.68%
-25,967,000-21,167,000-30,595,000-37,476,000-30,104,00021,686,00024,298,00035,855,00033,174,00021,055,00062,692,00050,257,00048,089,00059,719,00036,592,00035,958,00054,346,00024,127,00025,014,000
CFO
24m
-54.52%
5,493,000-32,054,00010,723,00038,934,00063,266,000-63,189,00051,628,00028,991,00039,111,00062,308,00082,854,00055,783,00025,033,00060,352,00093,644,000-69,924,00061,220,00053,686,00024,414,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, researches, develops, produces, and sells medicines in the People's Republic of China. It is also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology products. In addition, the company manufactures herbal medicines and generic drugs products, as well as medical devices. The company is based in Shenzhen, the People's Republic of China. Shenzhen Neptunus Interlong Bio-technique Company Limited is a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
URL
https://www.interlong.com/
IPO date
Sep 12, 2005
Employees
1,453
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT